Blue Jet Healthcare Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
BLUEJET · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 9.0 pts more than Nifty Smallcap 250 and 9.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Blue Jet Healthcare reported FY26 revenue of ₹10,299.85 million, up 5.8% from ₹9,732.1 million in FY25. Profit after tax grew 23.1% to ₹3,052.03 million from ₹2,478.16 million, with EPS of ₹17.59 vs ₹14.29 year earlier. The Board recommended a final dividend of ₹1.2 per share (60% payout). The company also proposed raising up to ₹10,000 million through QIP, preferential issue, or private placement. Capital work in progress increased significantly to ₹3,013.76 million from ₹888.84 million, indicating major expansion. Statutory auditors KKC & Associates issued an unmodified opinion with no qualifications.
Strong profit growth and clean audit support a positive outlook; however, the large proposed fund raise could dilute shareholder value. The significant expansion in capital work-in-progress suggests major capacity investments underway.